Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Oct 8 · inside the Ichimoku cloud · RSI 42 · MACD below its signal · 6% below its 52-week high
None of the 29 investors followed here reported a position in FBT in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a FBT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.1 | -2.0 | -3.8 | 2.0 | 8.7 | 11.3 | -1.1 | 9.0 | 1.9 | -4.6 | +25.7% | ||
| 2025 | 8.7 | -2.9 | -3.0 | -4.2 | -1.0 | 0.0 | 1.8 | 4.7 | 4.3 | 7.7 | 11.1 | -3.7 | +24.3% |
| 2024 | -5.8 | 1.2 | 2.0 | -6.4 | 3.5 | 3.3 | 8.7 | 1.9 | 0.8 | -1.0 | 2.3 | -4.5 | +5.2% |
| 2023 | 6.1 | -5.9 | 0.7 | -0.9 | -0.5 | 0.2 | 1.7 | -0.8 | -5.3 | -9.1 | 6.3 | 11.9 | +2.5% |
| 2022 | -8.2 | -1.6 | 1.9 | -9.0 | -0.7 | 0.5 | 3.4 | -2.7 | -3.2 | 8.7 | 8.5 | -1.0 | −4.8% |
| 2021 | 4.3 | -4.0 | -4.6 | 2.3 | -0.8 | 5.9 | -2.7 | 3.5 | -4.5 | -0.1 | -5.5 | 3.4 | −3.6% |
| 2020 | -4.6 | 1.3 | -8.7 | 15.5 | 9.2 | 1.4 | -1.2 | -3.1 | -2.1 | -2.9 | 5.5 | 4.2 | +13.0% |
| 2019 | 15.8 | 4.5 | 0.4 | -8.2 | -7.4 | 9.8 | -2.9 | -5.8 | -3.9 | 4.9 | 13.1 | 1.3 | +19.7% |
| 2018 | 13.0 | -4.1 | -1.5 | -0.7 | 6.1 | 0.0 | 5.8 | 6.2 | 0.8 | -15.6 | 4.7 | -11.3 | −0.3% |
| 2017 | 5.7 | 8.6 | 1.0 | 2.0 | -2.6 | 9.0 | 1.8 | 7.0 | -0.2 | -2.3 | 3.6 | -0.6 | +37.1% |
| 2016 | -24.1 | -2.9 | 5.1 | 4.3 | 4.6 | -6.3 | 12.1 | -4.4 | 4.1 | -12.8 | 8.8 | -3.9 | −19.6% |
| 2015 | 7.7 | 4.8 | 2.6 | -5.7 | 10.8 | 0.4 | 1.9 | -11.0 | -9.9 | 3.0 | 7.7 | 0.6 | +10.8% |
| 2014 | 8.8 | 10.9 | -8.1 | -2.8 | 2.9 | 7.3 | -1.5 | 14.5 | -1.2 | 8.4 | 2.5 | 0.1 | +47.5% |
| 2013 | 7.7 | 2.4 | 7.2 | 5.7 | 2.9 | -1.5 | 9.5 | -4.1 | 6.0 | -0.8 | 7.0 | 0.6 | +50.6% |
| 2012 | 21.2 | -0.8 | 7.6 | 4.1 | -3.3 | 2.9 | -0.8 | 0.4 | 6.4 | -10.4 | 10.3 | 0.2 | +40.7% |
| 2011 | -1.2 | 0.0 | 6.7 | 6.8 | 1.1 | -1.5 | -7.3 | -11.8 | -7.7 | 6.3 | -8.3 | 1.4 | −16.5% |
| 2010 | 2.4 | 7.7 | 17.9 | -2.5 | -12.3 | -2.8 | 3.4 | 0.1 | 9.2 | 0.7 | -2.0 | 13.5 | +36.9% |
| 2009 | -1.9 | -5.7 | 7.5 | -1.5 | 1.9 | 7.7 | 24.8 | 6.4 | -0.3 | -11.0 | 8.0 | 6.1 | +45.0% |
| 2008 | -4.9 | -3.3 | 1.7 | 1.5 | 1.5 | -4.0 | 17.3 | -3.7 | -6.3 | -14.1 | -11.4 | 8.5 | −19.2% |
| 2007 | 2.5 | -3.9 | 3.1 | 7.7 | -0.2 | -5.8 | -2.2 | 2.1 | 5.6 | 2.4 | -1.7 | -5.1 | +3.5% |
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of 30 leading biotechnology companies.